Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wang, Y, Thongsawat, S, Gane, E J, Liaw, Y-F, Jia, J, Hou, J, Chan, H L Y, Papatheodoridis, G, Wan, M, Niu, J, Bao, W, Trylesinski, A, Naoumov, N V
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2013
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618368/
https://ncbi.nlm.nih.gov/pubmed/23490388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.12025
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi